Alternative payment models and innovation: A case study of US health system adoption of a sacubitril/valsartan to treat acute decompensated heart failure.
This study used a decision tree model to assess the financial impact of health system adoption of sacubitril/valsartan to treat acute decompensated heart failure (ADHF). A comparator scenario modelled current health care utilization and cost for treating hospitalized ADHF patients with angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARB). The study then measured the impact of adopting sacubitril/valsartan to treat ADHF on health system economic outcomes. Differences in treatment efficacy were based on the PIONEER-HF clinical trial. The financial impact of changes in patient outcomes under ...
Source: Journal of Medical Economics - September 20, 2020 Category: Health Management Tags: J Med Econ Source Type: research

The six delta platform for outcome-based contracting for pharmaceuticals.
Authors: Alkhatib NS, Abraham I PMID: 32930629 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - September 18, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Comparison of hospital length of stay of acute ischemic stroke patients with non-valvular atrial fibrillation started on rivaroxaban or warfarin treatment during hospitalization.
Conclusions: The rivaroxaban users had a 3-day shorter LOS-OAC after IPTW-adjustment. Using rivaroxaban was associated with a 4 to 5 days shorter LOS-OAC than using warfarin in patients with mild or moderate stroke, though treatment selection did not have a large impact in patients with severe stroke. PMID: 32936057 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - September 18, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus nab-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system.
Conclusions: The SP142 assay demonstrated to be a dominant alternative compared to 22C3 to guide the treatment with atezolizumab plus nab-paclitaxel in patients with aTNBC. PMID: 32897765 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - September 9, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US.
Authors: Milentijevic D, Germain G, Laliberté F, Bookhart BK, MacKnight SD, Tsang J, Lefebvre P Abstract Objectives: To provide the most current assessment of real-world healthcare resource utilization (HRU) and costs among patients with NVAF who newly initiated rivaroxaban and apixaban using a large US database.Material and Methods: A retrospective weighted cohort design was used with healthcare insurance claims from the Optum Clinformatics Data Mart databases (01/2012-12/2018). The index date was defined as the first dispensing of rivaroxaban or apixaban. Adult NVAF patients with an index date on or after ...
Source: Journal of Medical Economics - September 9, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
Conclusions: Osimertinib is not cost effective as a first-line treatment compared to standard EGFR TKIs in advanced EGFR mutant NSCLC patients in Singapore. The findings from our evaluation, alongside other considerations including the lack of survival benefit in the Asian subgroup of the FLAURA trial, will be useful to inform policy makers on funding decisions for NSCLC treatments in Singapore. PMID: 32886557 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - September 6, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Pricing methods in outcome-based contracting: Integration analysis of the six dimensions (6 δs).
Conclusions: We demonstrated that the integration of the prices from the six dimensions of the Six Delta platform and market conditions is feasible and yields multidimensional prices estimates to support outcome-based pricing/contracting. PMID: 32845180 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - August 29, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Economic burden and risk factors of migraine disease progression in the US: A retrospective analysis of a commercial payer database.
Authors: Foster SA, Chen CC, Ding Y, Mason O, McGuiness CB, Morrow P, Ye W, Wade RL, Smith TR, Joshi S Abstract Aims: To evaluate the prevalence and risk factors of migraine progression and to assess the incremental burden of migraine progression on healthcare systems.Materials and methods: Adult patients were required to have a migraine diagnosis in IQVIA's US adjudicated claims database between 1/1/2012 and 6/30/2016, continuous enrollment ≥12 months before and after the index date (i.e., the first observed migraine diagnosis) and ≥1 additional migraine diagnosis claim during the 12-month post-index period....
Source: Journal of Medical Economics - August 29, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Pricing methods: δ3: Reference-based pricing.
Conclusions: We demonstrated that international price referencing methods can be integrated into our proposed Six Delta platform for outcome-based pricing/contracting. PMID: 32845191 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - August 29, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Pricing methods in outcome-based contracting: δ2: Willingness-to-pay-based pricing.
Conclusions: We demonstrated that WTP-based methods that include various WTP thresholds and market conditions generate price estimates across these thresholds and market conditions that can be integrated into our proposed Six Delta platform for outcome-based pricing/contracting. PMID: 32845201 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - August 29, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Pricing methods in outcome-based contracting: δ5: Risk of efficacy failure-based pricing.
Conclusions: We demonstrated that pricing methods based on risk of efficacy failure methods can be integrated into our proposed Six Delta platform for outcome-based pricing/contracting. PMID: 32845204 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - August 29, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Pricing methods in outcome-based contracting: δ4: Safety-based pricing.
Conclusions: We demonstrated that ex ante pricing methods-based paybacks for safety issues leading to treatment discontinuation can be integrated into our proposed Six Delta platform for outcome-based pricing/contracting. PMID: 32845205 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - August 29, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Pricing methods in outcome-based contracting: δ6: Adherence-based pricing.
Conclusions: We demonstrated that adherence-based pricing methods can be integrated into our proposed Six Delta platform for outcome-based pricing/contracting. The proof-of-concept exercise needs to be expanded with the in-arrear pricing method based on real world data to be secured. PMID: 32845209 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - August 29, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Pricing methods in outcome-based contracting: δ1: Cost effectiveness analysis and cost-utility analysis-based pricing.
Conclusions: We demonstrated that conventional CEA and CUA methods generate price estimates at varying levels of certainty that can be integrated into our proposed Six Delta platform for outcome-based pricing/contracting. PMID: 32845794 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - August 29, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid and Medicare Insurance - The perspective of private and public payers.
Conclusions: A high proportion of patients experienced VOCs across payers. Furthermore, inpatient and SCD-related costs accounted for a significant proportion of total all-cause healthcare costs, which increased with VOC frequency. PMID: 32815766 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - August 22, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
Conclusions: Insulin degludec was projected to be cost-effective or dominant versus other basal insulins for the treatment of T1D and T2D in Sweden. PMID: 32746676 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - August 13, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective.
Conclusions: Our analysis showed tisagenlecleucel use in r/r DLBCL patients who failed at least 2 prior lines of systemic therapies was associated with exceedingly high ICER, which is unlikely to represent good use of healthcare resources. Comparative clinical evidence from the ongoing trials might provide more insight into future evaluations. PMID: 32780608 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - August 13, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Dehydrated human amnion and chorion allograft versus standard of care alone in treatment of Wagner 1 diabetic foot ulcers: A trial-based health economics study.
CONCLUSIONS: The results of this study demonstrated that dHACA added to SOC compared to SOC alone was extremely cost-effective in the defined trial population. PMID: 32729342 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - July 31, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand.
Conclusions: Infliximab for the treatment of refractory moderate-to-severe CD in Thailand would be cost-effective if the drug prices were significantly decreased. The best value for money strategy was infliximab biosimilar with a restricted duration of treatment. Key pointsThe use of infliximab and its biosimilar in a restricted duration of maximum 5-year is not cost-effective for patients with moderate-to-severe Crohn's disease refractory to conventional therapy, unless their price was lowered around 72-90% in Thailand.The estimated budget impact for adopting infliximab or its biosimilar for such indication has potential ...
Source: Journal of Medical Economics - July 31, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost-utility analysis of normothermic liver perfusion with OrganOx compared to static cold storage in the United Kingdom.
Conclusions: Use of OrganOx metra for the perfusion and transportation of livers prior to transplantation is a cost-effective strategy. Key Points for Decision MakersIntroduction of OrganOx metra into NHS could increase the utilisation of donated livers with patients experiencing lower rates of early allograft dysfunction and adverse events, compared with current practice.Results of the economic analysis indicate that the OrganOx metra is highly likely to be cost-effective and result in improved patient outcomes. PMID: 32729749 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - July 31, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness and budget impact analysis of a patient visit support system for blindness reduction in Japanese patients with glaucoma.
Conclusion: Introduction of this support system with SoC is cost-effective and will lead to blindness reduction in Japanese patients with glaucoma. Over a 20 year period, it will lead to an overall cost savings of 1,132 billion yen (10 billion US dollars) for the Japanese healthcare system. PMID: 32729756 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - July 31, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Health-related quality of life, work productivity and costs related to patients with inflammatory bowel disease in Austria.
Authors: Walter E, Hausberger SC, Groß E, Siebert U Abstract Objective: Inflammatory-Bowel-Disease (IBD) is a lifelong illness with significant impact on health-related-quality-of-life (HRQoL). The disease-burden causes work productivity impairment, such as sick-leave and restriction of leisure time activities. From a societal perspective, productivity loss often contributes significantly to the total costs. The aim of the study is to analyze the impact of disease-burden on work productivity, daily activities, and HRQoL.Methods: We performed a survey among Austrian patients with IBD to assess general question...
Source: Journal of Medical Economics - July 28, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Fraudster's and victims' profiles and loss predictors' hierarchy in the mental healthcare industry in the U.S.
Conclusions. This study empirically justifies considering loss, due to healthcare fraud, from a multi-level perspective. Identified typical fraudster's and respective victim's profiles helped to elaborate on specific practical recommendations aimed at fraud prevention in the mental healthcare system in the U.S. PMID: 32713224 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - July 28, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Rational drug use in hospital settings - areas that can be changed.
Authors: Religioni U, Pakulska T PMID: 32715825 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - July 28, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Health care resource utilization and burden of disease in a U.S. Medicare population with a principal diagnosis of osteoarthritis of the knee.
CONCLUSIONS: Many Medicare beneficiaries received care for knee OA, and these patients had significantly greater HCRU than those with the absence of knee OA, totaling over $34 billion in healthcare expenditures in 2014. PMID: 32715848 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - July 28, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: The Chronic Constipation and IBS-C Treatment and Outcomes Real-world Research Platform (CONTOR).
Conclusions: By combining administrative claims and patient-reported data over time, CONTOR afforded a deeper understanding of the IBS-C/CIC patient experience than could be achieved with 1 data source alone; for example, participants self-reported burdensome symptoms and treatment dissatisfaction despite making few treatment changes, highlighting an opportunity to improve patient management. This patient-centric approach to understanding real-world experience and management of a chronic condition could be leveraged for other conditions in which the patient experience is not adequately captured by standardized data sources...
Source: Journal of Medical Economics - July 24, 2020 Category: Health Management Tags: J Med Econ Source Type: research

A budget impact analysis of lenalidomide in multiple myeloma Egyptian patients.
Conclusion: The results of our BI models suggest that not only does RD treatment have an effect on the budget, but also has major cost savings in other areas which are very important while considering the total costs of MM treatment. This study results provided evidence-based information to the MoH that will help in decision making of whether to implement RD as a treatment intervention or not. PMID: 32669063 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - July 17, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Composite outcome measurement in clinical research: The triumph of illusion over reality?
Authors: McKenna SP, Heaney A Abstract Composite measures that combine different types of indicators are widely used in medical research; to evaluate health systems, as outcomes in clinical trials and in patient-reported outcome measurement. The potential advantages of such indices are clear. They are used to summarise complex data and to overcome the problem of evaluating new interventions when the most important outcome is rare or likely to occur far in the future. However, many scientists question the value of composite measures, primarily due to inadequate development methodology, lack of transparency or the li...
Source: Journal of Medical Economics - July 17, 2020 Category: Health Management Tags: J Med Econ Source Type: research

A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology.
Conclusions: Structural uncertainty in economic modelling is rarely explored due to time and resource limitations. This comparison of structural approaches indicates that the choice of structure may have a profound impact on cost-effectiveness results. This highlights the importance of carefully considered model conceptualization, and the need for further research to ascertain when it may be most appropriate to use each approach. PMID: 32673128 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - July 17, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Use of real-world evidence in meta-analyses and cost-effectiveness models.
The objectives of this communication were to (1) summarise all guidance on how to conduct an RWE meta-analysis (MA) and how to develop an RWE cost-effectiveness model, (2) to describe our experience, challenges faced and solutions identified, (3) to provide recommendations on how to conduct such analyses.No formal guidelines on how to conduct an RWE MA or to develop an RWE cost-effectiveness model were identified. Using the context of non-vitamin K antagonist oral anticoagulants (NOACs) in stroke prevention in atrial fibrillation, we conducted an RWE MA, after having identified sources of uncertainty. We then implemented t...
Source: Journal of Medical Economics - July 14, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants.
Conclusions: HRU and costs from HCT to PTLD were high and more than doubled within 1-year post-PTLD. PTLD patients who died had ∼7 times higher costs than those who lived, driven by hospitalizations. Effective treatments are needed to reduce the burden of PTLD. PMID: 32643493 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - July 11, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Health state utilities associated with caring for an individual with cutaneous T-cell lymphoma (CTCL).
Conclusions: These findings highlight the substantial burden of caring for an individual with CTCL and the importance of including caregiver burden in the health technology assessment review process. A limitation is the hypothetical vignette approach, which meant the TTO participants did not have experience of caring for individuals with CTCL, but were imagining this state. There is also the possibility that they may also be considering the patient experience when responding to the questions. PMID: 32644862 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - July 11, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients.
Conclusions: The cost-effectiveness of G + Chemo is acceptable in Japan. Differences in the direct medical costs among treatment regimen groups were mostly due to hospitalization costs. This is probably because many Japanese hematologists choose inpatient treatments over outpatient treatments in CHOP-based induction therapy. PMID: 32620061 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - July 7, 2020 Category: Health Management Tags: J Med Econ Source Type: research

The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
Conclusion: The results of this analysis can serve as a foundation to introduce HRQoL-based recommendations for the use of biologics in the management of IBD in Saudi Arabia. PMID: 32619388 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - July 4, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs.
Authors: Manceur AM, Ding Z, Muser E, Obando C, Voelker J, Pilon D, Kinkead F, Lafeuille MH, Lefebvre P Abstract Aims: To quantify the long-term direct and indirect costs among patients with Crohn's disease (CD) and specific subgroups of these patients in the United States from the private payer's perspective.Materials and Methods: This retrospective study used the OptumHealth Care Solutions, Inc database (01/01/1999-03/31/2017) to match (1:5) adult patients with ≥2 claims for CD to patients without inflammatory bowel disease (IBD). Patterns observed during follow-up (i.e., biologics, opioids, or steroids; CD-re...
Source: Journal of Medical Economics - July 3, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Diagnostic and lifetime hospital costs of patients suffering from wild-type transthyretin amyloid cardiomyopathy in Denmark.
Conclusions: Caring for patients with ATTRwt places a significant economic burden on the healthcare system. The study emphasizes the cost saving potential for medical interventions in this patient population. PMID: 32609021 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - July 3, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Understanding patients' preferences for HIV treatment among rural and urban Colombian patients.
Authors: Hiligsmann M, Cheung KL PMID: 32594810 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - July 1, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Costs of in-house genomic profiling and implications for economic evaluation: A case example of non-small cell lung cancer (NSCLC).
CONCLUSIONS: When conducting economic evaluation to assess the value of introducing external tests, it is critical that non-material costs of standard testing strategies be measured and incorporated. PMID: 32597288 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - July 1, 2020 Category: Health Management Tags: J Med Econ Source Type: research

At a glance: Economic impact of industry-sponsored clinical trials of pharmaceutical products.
Authors: Varmaghani M, Heidari E, Reiner Ž, Sahebkar A PMID: 32580595 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - June 27, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Clinical and economic burden of postsurgical complications of high-risk surgeries: A cohort study in Thailand.
Conclusions: Postsurgical complications are a serious problem in Thailand, as they are associated with worsening mortality risk, LOS, and healthcare costs. Clinicians should develop interventions to prevent or effectively treat postsurgical complications to mitigate such burdens. PMID: 32580609 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - June 27, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Analysis of treatment cost for neuroblastoma to the family: A single-center cross-sectional study in China.
CONCLUSION: Direct non-medical and indirect costs play an important role in the total treatment costs of NB. Children with NB treated in local hospitals and followed up in hospital specialized in childhood oncology may save many unnecessary expenses. China's healthcare system should establish mechanisms and provide financial support for children with NB. PMID: 32568600 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - June 24, 2020 Category: Health Management Tags: J Med Econ Source Type: research

The relative efficiency of schizophrenia health care systems: an international comparison using data envelopment analysis.
CONCLUSIONS: In this international DEA, despite the difference in schizophrenia disease investment across countries, there was little difference in output as measured by DALYs per patient. Potentially, Lithuania, Norway, Switzerland and the US should be considered 'benchmark' countries by policy makers, thereby providing useful information to countries with less efficient systems. PMID: 32573296 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - June 24, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Willingness to pay threshold: A Japanese perspective.
Authors: Petrou P Abstract The willingness-to-pay threshold has emerged as a significant tool in the decision-making process. The elucidation of a rational threshold is still embroiled in controversy. Several studies contributed to the identification not only of a threshold but of several variables that influence the outcome as well. In a recent study in Japan, the maximum threshold was estimated at JPY 14,900,000 (US$139,680). Of note was also the identification of disease state and time as important factors that exert influence on the final outcome. PMID: 32552089 [PubMed - as supplied by publisher] (Source: ...
Source: Journal of Medical Economics - June 21, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Subscriber continuity in health insurance plans: factors associated with reenrollment and coverage changes.
In this study we examined the extent to which Marketplace health insurance subscribers reenroll a second year. Among reenrollees, we sought to examine movement to more and less generous insurance plans (based on actuarial value), and the extent to which adverse selection, adverse retention, and aging in place are evident from reenrollment choices made.Methods: Reenrollment from 2015 to 2016 and 2016 to 2017 and movement to more and less generous insurance plans was examined using enrollment and insurance claims data from two U.S. Federally-facilitated Marketplace insurance carriers operating in the state of New Mexico for ...
Source: Journal of Medical Economics - June 11, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Estimating health state utilities associated with a rare disease: Familial chylomicronemia syndrome (FCS).
Conclusions: The vignette-based approach is useful for estimating utilities of a rare disease. The health state utilities derived in this study would be useful in models examining cost-effectiveness of treatments for FCS. PMID: 32479143 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - June 3, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Economic and humanistic burden associated with noncommunicable diseases among adults with depression and anxiety in the United States.
Conclusions: 60% of patients with MDD and/or AAD had at least one additional NCCD, which significantly increased the economic and humanistic burden. These findings are important for payers and clinicians in making treatment decisions. These results underscore the need for development of multi-pronged interventions which aim to improve quality of life and reduce activity limitations among patients with mental health disorders and NCCDs. PMID: 32468879 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - May 31, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Economic analysis of Innovo ® neuromuscular external electrical stimulation device for the treatment of stress urinary incontinence: A UK-based cost-utility analysis.
Conclusions: INNOVO® is a potentially cost-effective treatment option for patients with SUI who have failed first-line treatment. It could reduce costs to the health care service and improve quality-of-life for selected patients over their lifetime. PMID: 32468884 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - May 31, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Preeclampsia in Switzerland: A cost analysis in two hospitals.
Conclusion: This is the first study to analyze costs for preeclampsia in Switzerland. It would be desirable if this cost analysis were to be performed in other hospitals in order to achieve greater representativity for Switzerland. PMID: 32462948 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - May 30, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
CONCLUSION: While pembrolizumab is superior to standard chemotherapy in improving overall survival and progression-free survival, results suggest that it is unlikely to be cost-effective at its current price in Singapore. Factors including clinical effectiveness, safety and budget impact should also be considered when making national funding decisions. PMID: 32462958 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - May 30, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: Recent evidence from pharmacoeconomics.
Conclusions: The fundamental disconnect between drug pricing and innovation costs demands public attention and policy intervention, which remain largely elusive to date. Gaming the system in the name of invention and discovery to reap additional benefits at the expense of consumer health and income brings to question the offsetting benefits of firm innovation, besides raising separate issues of fairness and equity. Innovation needs to be considered from the perspective of value lines and beyond traditional incentives to drug utilization, with or without insurance coverage. Cost-effectiveness and cost-benefit analyses will ...
Source: Journal of Medical Economics - May 22, 2020 Category: Health Management Tags: J Med Econ Source Type: research